The FDA is using the president’s 2027 budget proposal to outline new policies aimed at shortening the path to first-in-human studies and increasing U.S.-based drug development and manufacturing, according to budget documents and reporting. Key proposals include making the rare pediatric disease priority review voucher program permanent and creating an optional, risk-based expedited Investigational New Drug pathway that could allow some candidates to start Phase 1 with less burden if adequate preclinical data exist. Separately, the FDA is also proposing a “clinical trial notification pathway” as an alternative to the traditional IND system, framed as a way to reduce cost and delay in early-stage development. For biotech, the package signals a renewed regulatory push to counter non-U.S. dominance in early clinical development while trying to improve predictability for sponsors and reduce administrative friction for studies that use existing evidence.